Regenxbio Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 228.91, 259.53, 350.35, 574.81, 809.16 ], "ebit_estimate": [ -148.09, -144.9, -115.62, -4.26, 183.06 ], "ebitda_estimate": [ -148.77, -161.99, -92.93, 37.95, 199.28 ], "net_income_estimate": [ -160.32, -150.77, -140.02, 3.68, 198.73 ], "per_share_eps_estimate": [ -3.48, -2.42, -2.56, 0.19, 3.06 ], "eps_nri_estimate": [ -2.75, -2.55, -2.12, 0.19, 3.06 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 1.88, 3.65, -0.58, null, null ], "pretax_income_estimate": [ -177.67, -213.23, -136.74, -0.49, 187.26 ], "operating_cash_flow_per_share_estimate": [ -2.27, 0.99, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ -180.6, -144.38, null, null, null ], "gross_margin_estimate": [ 92.5, 78, 76, 79.5, 81.5 ], "operating_cash_flow_estimate": [ -119.01, 51.9, null, null, null ], "pettm_estimate": [ 0, 0, 0, 73.42, 4.56 ], "long_term_growth_rate_mean": 16.46, "long_term_revenue_growth_rate_mean": "25.70", "future_per_share_eps_estimate_growth": 14.1, "future_eps_nri_estimate_growth": 16.46, "future_revenue_estimate_growth": 25.7, "future_ebit_estimate_growth": 9.67, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 9.86, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -5.95, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ 119.09, 33.45, 70.8, 97.73, 48.73, 81.73, 43.64, 41.75 ], "ebit_estimate": [ 15.43, -58.91, -25.04, 9.61, -41.35, -7.49, -50.56, -62.83 ], "ebitda_estimate": [ 32.56, -61.89, -54.97, -67, -62, -62, -61, -58.97 ], "net_income_estimate": [ 9.81, -64.89, -31.82, 6.11, -44.85, -10.99, -54.06, -62.83 ], "per_share_eps_estimate": [ 0.17, -1.24, -0.71, -0.3, -0.91, -0.28, -0.81, -0.71 ], "eps_nri_estimate": [ 0.22, -1.21, -0.56, -0.3, -0.91, -0.28, -0.73, -0.71 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ 9.27, -61.2, -21.16, 6.11, -44.85, -10.99, -54.06, -62.83 ], "operating_cash_flow_per_share_estimate": [ 1.03, 9.49, 17.84, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ 97.5, 85, 85, 80, 80, 80, 80, 82 ], "operating_cash_flow_estimate": [ 54, 497.54, 935.32, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 16.46, "long_term_revenue_growth_rate_mean": "25.70", "future_per_share_eps_estimate_growth": 14.1, "future_eps_nri_estimate_growth": 16.46, "future_revenue_estimate_growth": 25.7, "future_ebit_estimate_growth": 9.67, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 9.86, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -5.95, "future_operating_cash_flow_per_share_estimate_growth": null }